FDA approved Ameluz to treat superficial basal cell carcinoma skin cancer.
Third quarter product revenue rose 30% year over year to $9.1 million.
Cash and cash equivalents fell to $3.2 million on Sept. 30, 2026.
On its third-quarter 2026 earnings call, held on Nov. 13, 2026, Biofrontera (NASDAQ:BFRI) announced that the Food and Drug Administration approved its prescription topical gel Ameluz to treat superficial basal cell carcinoma, expanding its label into skin cancer treatment. Accessing a second approved indication allows the business to target broader clinical demand without expanding its commercial field team. Three things management said stand out.
Securing approval for superficial basal cell carcinoma, a common skin cancer, creates a second indication for Ameluz, the company's light-activated topical treatment gel. Because dermatologists can administer the drug using red light illumination lamps already in their offices, Biofrontera can grow prescription volume through its established commercial infrastructure.
On September 9, the FDA approved Ameluz photodynamic therapy for the treatment of superficial basal cell carcinoma in adults. That makes Ameluz the first PDT approved in The United States to treat a skin cancer.
-- Hermann Luebbert, Chief Executive Officer, Chairman, and Founder
An International Trade Commission order previously blocked Biofrontera from importing its large-panel illumination lamp, temporarily restricting drug sales to affected dermatology clinics. Obtaining U.S. Customs clearance for a redesigned lamp allows the company to resume hardware deliveries and restore drug sales to existing customers.
US Customs and Border Protection ruled that our redesigned large field lamp which we called RhodoLED XLC, does not infringe the asserted claims of the DUSA Pharmaceutical patents...
-- Hermann Luebbert, Chief Executive Officer, Chairman, and Founder
Biofrontera closed the quarter with $3.2 million in cash and cash equivalents, down from $6.4 million at year-end 2025. Rising legal fees and lamp remediation costs pushed operating expenses higher, and management plans to draw on a line of credit and collect a milestone payment to fund ongoing operations.
management has concluded that, substantial doubt exists about the company's ability to continue as a going concern for at least 12 months From the issuance of our form 10 q.
-- Eugene Frederick Leffler, Chief Financial Officer
Product revenues reached $9.1 million in the third quarter as sales volume expanded. Biofrontera relies on structural advantages, including an installed base of 853 light devices across 742 clinics, to sell new indications without adding sales reps. Management is watching cash discipline and commercial launch execution.
We are seeing significant momentum in our business. All key sales metrics were positive year-over-year, both in Q3 as well as the first 9 months of the year.
-- George Jones, Chief Commercial Officer
With a third label expansion filed for bodywide treatment of actinic keratosis, Biofrontera aims to deepen clinic utilization while managing liquidity.
What has changed is what we have to sell. 2 indications today and a third filed all delivered through the lamps and the sales force already in place.
-- Hermann Luebbert, Chief Executive Officer, Chairman, and Founder
Before you buy stock in Biofrontera, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Biofrontera wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $327,620!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $959,410!*
Now, it’s worth noting Stock Advisor’s total average return is 802% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 17, 2026.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.